描述了在碱性条件下使用(溴二氟甲基)膦酸二乙酯 ( 1 )对各种基于S - 和O - 的亲核试剂进行有效二氟甲基化,呈现出广泛的 p K a值。这些反应依赖于通过1水解形成的二氟卡宾的定量产生,发现只有当起始材料的 p K a值小于约1时才有效。11. 重要的是,在底物具有两个或三个亲核中心的情况下,该特征成功实现以实现中心的高化学或区域选择性二氟甲基化,表现出最低的 p K一个值和最高极化。
Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity
申请人:——
公开号:US20020120011A1
公开(公告)日:2002-08-29
The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N,N-disubstituted diamines. A preferred specific N,N-disubstituted diamine is the compound:
1
[EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2009062308A1
公开(公告)日:2009-05-22
Compounds of formula (I): wherein c, X, Y, R2, R4 and R5 are defined herein, are useful as inhibitors of HIV replication.
式(I)的化合物:其中c、X、Y、R2、R4和R5如本文所定义,可用作HIV复制的抑制剂。
[EN] PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS<br/>[FR] COMPOSÉS ANTAGONISTES DU RÉCEPTEUR DE LA PROSTAGLANDINE EP4
申请人:HEPTARES THERAPEUTICS LTD
公开号:WO2021069927A1
公开(公告)日:2021-04-15
The disclosures herein relate to novel compounds of formula (1): (1) and salts thereof, wherein A, X, R1, R2, R3, R4, R10 and R11 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EP4 receptors.
(R)-chiral halogenated substituted N-benzyl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
申请人:——
公开号:US20020177708A1
公开(公告)日:2002-11-28
The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.
[EN] TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE<br/>[FR] INHIBITEURS DE TRIAZOLOPYRIDINE DE LA MYÉLOPEROXYDASE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2017040450A1
公开(公告)日:2017-03-09
The present invention provides compounds of Formula (I): wherein A, Y and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.